Nu-Med Plus Faces Imminent Funding Crisis, Funded Only Through June 30, 2026
NUMD has more than doubled off its 52-week low of $0.008 on elevated volume (2.1× avg).
Summary
Nu-Med Plus, Inc. is in severe financial distress, with cash reserves sufficient only until June 30, 2026, and requires $2.1 million in new funding to continue operations and product development.
Key Events · Earnings and Guidance · NUMD
-
Going Concern Warning
Management explicitly states substantial doubt about the company's ability to continue as a going concern, reiterating concerns from the prior 10-K.
-
Imminent Funding Deadline
The company is currently funded only through June 30, 2026, highlighting an extremely short cash runway.
-
Critical Cash Position
Cash on hand as of March 31, 2026, was only $4,284.
-
Significant Funding Gap
Nu-Med Plus requires approximately $2.1 million in additional financing for the next 12 months to cover overhead and product development, a sum far exceeding its current market capitalization.
Analysis · NUMD · Industrial Applications And Services
Nu-Med Plus, Inc. has reported an extremely critical financial situation, explicitly stating substantial doubt about its ability to continue as a going concern. The company's cash reserves are minimal, and it is funded only through June 30, 2026, indicating an imminent need for capital. Product development remains suspended due to a lack of funding, and the company requires $2.1 million over the next 12 months, a sum significantly exceeding its current market valuation. This quarterly report provides an urgent update to the severe financial distress previously disclosed in the 10-K filed last month.
At the time of this filing, NUMD was trading at $0.02 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $0.01 to $0.14. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.